Why should glucose-6-phosphate dehydrogenase (G6PD) level be checked before treating malaria?

Why G6PD Testing is Essential Before Malaria Treatment

G6PD level must be checked before treating malaria because certain antimalarial drugs—specifically primaquine and tafenoquine used for radical cure of P. vivax and P. ovale—can cause severe, potentially life-threatening hemolytic anemia in patients with G6PD deficiency. 1

The Critical Drug-Deficiency Interaction

Drugs That Require G6PD Testing

The 2024 European guidelines explicitly mandate G6PD testing before prescribing:

• Primaquine (15 mg base): Used for anti-relapse treatment at 30 mg/day for 14 days, with listed adverse effect of "haemolytic anaemia in G6PD deficiency" 1
• Tafenoquine (150 mg): Single 300 mg dose for radical cure, also causing "haemolytic anaemia in G6PD deficiency" 1

Both drugs target hepatic hypnozoites (dormant liver stages) of P. vivax and P. ovale that cause relapsing malaria. Without these medications, patients experience recurrent infections, but administering them without G6PD testing risks severe hemolysis.

The Clinical Consequences of Untested Treatment

Real-world evidence demonstrates the danger: when primaquine is prescribed without prior G6PD testing, patients develop iatrogenic severe hemolysis requiring emergency management 2. The case series from 2019 showed that:

• Patients presented with symptomatic anemia during treatment
• G6PD deficiency diagnosis became elusive during acute hemolysis
• Other medical treatments also posed hemolytic risks in these patients
• Healthcare providers struggled with proper management

Variant-Specific Risk Stratification

The guidelines specify different management based on G6PD variant type 1:

• African variant (A-): Mild deficiency, relatively resistant to severe primaquine-induced hemolysis
• Mediterranean variant (B-): Very high risk of severe hemolysis, may occur even with extended dosing regimens

For patients with intermediate G6PD deficiency (30-70% activity) and non-Mediterranean variant, weekly primaquine (0.75 mg base/kg, maximum 45 mg) for 8 weeks with close monitoring is recommended 1.

Testing Thresholds and Clinical Decision-Making

For Primaquine

• Test for G6PD deficiency before prescribing
• If deficient (<30% activity): use alternative weekly dosing regimen
• If intermediate (30-70%): weekly dosing with close monitoring (non-Mediterranean variant only)

For Tafenoquine

• Requires quantitative G6PD testing
• Do not use if <70% of adjusted male median 1
• More stringent threshold than primaquine

Geographic and Population Considerations

G6PD deficiency prevalence varies dramatically:

• Indonesia: 0-25.9% allele frequency across different regions, with 15 class B variants identified 3
• Sub-Saharan Africa: Ranges from <1% to 23.9%, with male predominance 4
• Myanmar: Approximately 10% in malaria-infected populations, with G6PD Mahidol (G487A) as major variant 5

This heterogeneity means universal testing is essential—you cannot predict deficiency based on ethnicity alone in clinical practice.

Common Pitfalls to Avoid

1. Timing of testing: G6PD enzyme activity measurements can be unreliable during acute hemolysis or recent blood transfusion 2

2. Female carriers: Women with intermediate activity (30-70%) are often missed but still at risk. The guidelines show 0.8-44.6% of females have deficient or intermediate activity across studied sites 3

3. Pediatric considerations: G6PD activity decreases in children aged 1-5 years and plateaus thereafter, requiring age-appropriate interpretation 6

4. Pregnancy and breastfeeding: Primaquine and tafenoquine are contraindicated regardless of G6PD status 1

The Elimination Context

National malaria programs mandating daily primaquine dosing (for G6PD-normal individuals) make pre-treatment G6PD testing absolutely necessary 2. Without testing, G6PD-deficient individuals receiving standard daily dosing face severe hemolysis risk. Countries moving toward malaria elimination must establish field monitoring systems for post-primaquine treatment safety 5.

The manufacturer-recommended cutoff for the G6PD Standard Biosensor (≤4.0 U/gHb for deficient) is conservative but more reliable than percentage-based AMM calculations for categorizing truly deficient individuals 6.